aTYR PHARMA INC — Director's Dealing 2016

Jan 6, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2016-01-04

Reporting Person: Ravindran Sanuj K. (Chief Business Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-01-04	Employee Stock Option (right to buy)	$9.13	A	153000	Acquired	2026-01-04	Common Stock (153000)	Direct
2016-01-04	Employee Stock Option (right to buy)	$9.13	A	10750	Acquired		Common Stock (10750)	Direct

Footnotes

F1: 1/4th of the shares subject to this option shall vest and become exercisable on January 4, 2017 and the remaining shares subject to this option shall vest and become exercisable in 36 equal monthly installments, such that this option is fully exercisable on January 4, 2020. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.

F2: The shares subject to this option shall vest and become exercisable, if at all, in 48 equal monthly installments upon the achievement of certain performance goals, which must be achieved by January 4, 2018, or such option will be subject to immediate forfeiture. This option is subject to accelerated vesting upon termination without cause upon a change of control of the issuer.